SCHEMBL30714731

SCHEMBL30714731

Cn1nccc1COc1ccc2nn(C)c(C(=O)NCc3cccc(O)n3)c2c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGDS O60760 1/20 0.41
KMT2A Q03164 2/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
RAB9A P51151 5/20 0.35
NPC1 O15118 4/20 0.35
MMP13 P45452 1/20 0.35
SLC8A1 P32418 1/20 0.34
ALDH1A1 P00352 5/20 0.34
LMNA P02545 3/20 0.34
KDM4E B2RXH2 3/20 0.34
HPGD P15428 2/20 0.34
HSD17B10 Q99714 2/20 0.34
USP2 O75604 1/20 0.34
GRM5 P41594 1/20 0.34
MAPK1 P28482 3/20 0.34
ADORA2A P29274 2/20 0.33
ALOX15 P16050 1/20 0.33
TSHR P16473 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
MAPT P10636 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30714607 0.87 MMP13 (0.47) KMT2AMMP13ALDH1A1TSHRSMN1; SMN2
SCHEMBL30714694 0.83 PDE10A (0.37) L3MBTL1RAB9ANPC1MMP13ALDH1A1
SCHEMBL30714643 0.82 PTGER4 (0.36) KMT2ARAB9ANPC1MMP13ALDH1A1
SCHEMBL30714704 0.79 HPGDS (0.38) HPGDSKMT2AL3MBTL1ALDH1A1KDM4E
SCHEMBL26696010 0.78 HPGDS (0.41) HPGDSKMT2AL3MBTL1RAB9ANPC1
SCHEMBL26696001 0.78 KDM4C (0.41) HPGDSKMT2AL3MBTL1ALDH1A1LMNA
SCHEMBL30714564 0.77 CNR1 (0.38) HPGDSKMT2AL3MBTL1RAB9ANPC1
SCHEMBL30714615 0.77 HPGDS (0.37) HPGDSKMT2AL3MBTL1ALDH1A1HPGD
SCHEMBL30714688 0.76 TP53 (0.40) HPGDSLMNAKDM4ECYP11B2
SCHEMBL30714697 0.76 HPGDS (0.44) HPGDSKMT2AL3MBTL1RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250376461-A1 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS UNIV LEUVEN KATH (BE) 2025-12-11 US disclosed
CN-119968362-A Indazole derivatives for the treatment of TRPM3 mediated disorders 勒芬天主教大学 2025-05-09 CN disclosed
EP-4499624-A2 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS Katholieke Universiteit Leuven KU Leuven Research & Development (BE) 2025-02-05 EP disclosed
WO-2023230540-A2 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-11-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250376461-A1 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS TRPV3, TRPM2, TRPV1 HPGDS 671/4885KMT2A 3017/4885L3MBTL1 4209/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.